Previous 10 | Next 10 |
Is Pacific Biosciences The Best Biotech Stock To Buy In The Stock Market Today? In the biotech world of genome sequencing, Illumina ( NASDAQ: ILMN ) may be the undisputed market leader. But when it comes to shareholder returns in the past year, Pacific Biosciences of California ...
The following slide deck was published by Invitae Corporation in conjunction with this event. For further details see: Invitae Corporation (NVTA) Presents At J.P. Morgan 39th Annual Healthcare Conference - Slideshow
Piper Sandler analyst Steven Mah has upgraded gene-sequencing biotech Pacific Biosciences of California (PACB) to overweight from neutral.His new price target is $52, up from $20.Mah bases his upgrade on the recent $900M cash infusion from Softbank and improved long-term outlook.Pacific Biosc...
Invitae to Present at the 10th Annual SVB Leerink Global Healthcare Conference PR Newswire SAN FRANCISCO , Feb. 10, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management t...
Invitae to Announce Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 17, 2021 PR Newswire SAN FRANCISCO , Feb. 3, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will...
Invitae Corporation ([[NVTA]] +3.7%) was downgraded by Oppenheimer to perform from outperform, noting the shares have reached firm’s previous price target of $51 after a ~12.7% surge in January.‘After raising our PT from $48 to $51 in early January, we do not view current valuat...
The coronavirus pandemic put a magnifying glass over existing inequities in healthcare, exposing major disparities that will impact underserved communities for generations to come if not addressed today. How can businesses in the digital health space -- think burgeoning genetic testing comp...
Invitae (NVTA) and clinical-stage biotech Decibel Therapeutics strike deal to launch Amplify, a no-charge genetic testing program to screen for the genetic cause of congenital hearing loss in children diagnosed with auditory neuropathy."We are pleased to collaborate with Invitae to ...
Are you excited about the potential of cutting-edge companies like CRISPR Therapeutics (NASDAQ: CRSP) , Fulgent Genetics (NASDAQ: FLGT) , or Invitae Corp. (NYSE: NVTA) ? You're not alone. The genetic testing market is expected to expand at a compound annual growth ra...
Invitae (NVTA) has priced its public offering of ~7.8M common shares at $51.50/share, for expected gross proceeds of ~$400M.Underwriters' over-allotment is an additional ~1.2M shares. Net proceeds will be used for working capital and other general corporate purposes, to acquire or invest in c...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...